Identification of coagulation-associated subtypes of lung adenocarcinoma and establishment of prognostic models-Reference-Cited by-同舟云学术

Identification of coagulation-associated subtypes of lung adenocarcinoma and establishment of prognostic models

Published:2023 Issue:6 Volume:20 Page:10626-10658
ISSN:1551-0018
Container-title:Mathematical Biosciences and Engineering
language:
Short-container-title:MBE

Author:

Han Mengyang¹,Wang Xiaoli¹,Li Yaqi¹,Tan Jianjun²,Li Chunhua²,Sheng Wang¹

Affiliation:

1. Department of Pharmacology, Beijing International Science and Technology Cooperation Base of Antivirus Drug, Faculty of Environment and Life, Beijing University of Technology, Beijing 100124, China

2. Department of Biomedical Engineering, Faculty of Environment and Life, Beijing University of Technology, Beijing 100124, China

Abstract

<abstract> <p>Lung adenocarcinoma (LUAD), the most common subtype of lung cancer, is a global health challenge with high recurrence and mortality rates. The coagulation cascade plays an essential role in tumor disease progression and leads to death in LUAD. We differentiated two coagulation-related subtypes in LUAD patients in this study based on coagulation pathways collected from the KEGG database. We then demonstrated significant differences between the two coagulation-associated subtypes regarding immune characteristics and prognostic stratification. For risk stratification and prognostic prediction, we developed a coagulation-related risk score prognostic model in the Cancer Genome Atlas (TCGA) cohort. The GEO cohort also validated the predictive value of the coagulation-related risk score in terms of prognosis and immunotherapy. Based on these results, we identified coagulation-related prognostic factors in LUAD, which may serve as a robust prognostic biomarker for therapeutic and immunotherapeutic efficacy. It may contribute to clinical decision-making in patients with LUAD.</p> </abstract>

Publisher

American Institute of Mathematical Sciences (AIMS)

Subject

Applied Mathematics,Computational Mathematics,General Agricultural and Biological Sciences,Modeling and Simulation,General Medicine

Reference32 articles.

1. F. Bray, J. Ferlay, I. Soerjomataram, R. L. Siegel, L. A. Torre, A. Jemal, Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA Cancer J. Clin., 68 (2018), 394–424. https://doi.org/10.3322/caac.21492

2. W. Chen, R. Zheng, P. D. Baade, S. Zhang, H. Zeng, F. Bray, et al., Cancer statistics in China, 2015, CA Cancer J. Clin., 66 (2016), 115–132. https://doi.org/10.3322/caac.21338

3. D. Yang, Y. Liu, C. Bai, X. Wang, C. A. Powell, Epidemiology of lung cancer and lung cancer screening programs in China and the United States, Cancer Lett., 468 (2020), 82–87. https://doi.org/10.1016/j.canlet.2019.10.009

4. R. Ruiz-Cordero, W. P. Devine, Targeted therapy and checkpoint immunotherapy in lung cancer, Surg. Pathol. Clin., 13 (2020), 17–33. https://doi.org/10.1016/j.path.2019.11.002

5. J. Vansteenkiste, L. Crinò, C. Dooms, J. Y. Douillard, C. Faivre-Finn, E. Lim, et al., 2nd ESMO consensus conference on lung cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up, Ann. Oncol. Off. J. Eur. Soc. Med. Oncol., 25 (2014), 1462–1474. https://doi.org/10.1093/annonc/mdu089